...
首页> 外文期刊>Journal of Contemporary Brachytherapy >Perineal recurrence of prostate ductal adenocarcinoma after transperineal brachytherapy: a case report and literature review
【24h】

Perineal recurrence of prostate ductal adenocarcinoma after transperineal brachytherapy: a case report and literature review

机译:前列腺导管腺癌的白宫复发术后颅内近衰退治疗:案例报告和文献综述

获取原文
           

摘要

Perineal recurrence after brachytherapy is an exceedingly rare complication. Moreover, ductal adenocarcinoma is a rare histological variant of prostate cancer. Herein, we describe a case of perineal recurrence from ductal adenocarcinoma of prostate after low-dose-rate brachytherapy (LDR-BT) in a 65-year-old male patient. The patient had localized prostate cancer, for which he received LDR-BT; however, he experienced perineal recurrence 2 years after receiving LDR-BT. Surgical excision was attempted, but we were unable to remove the whole tumor, owing to invasion to surrounding tissue. Pathological examination of resected tumor showed ductal adenocarcinoma of the prostate. External beam radiation therapy and high-dose-rate brachytherapy (HDR-BT) were performed for residual tumor. Mild mediastinal lymph node swelling was observed during clinical course of the disease. Hence, androgen deprivation therapy was administered with abiraterone after radiation therapy, and prostate-specific antigen level decreased to undetectable level. Biochemical failure after transperineal brachytherapy for prostate cancer should be considered as a perineal recurrence.
机译:近距离放射治疗后的会阴复发是一个非常罕见的并发症。此外,导管腺癌是前列腺癌的罕见组织学变体。在此,我们描述了在65岁的男性患者中低剂量速率近距离放射治疗(LDR-BT)后前列腺腺癌的会阴复发的情况。患者患有本地化的前列腺癌,他接受了LDR-BT;然而,他在接受LDR-BT后2年经历过一次性复发。尝试了手术切除,但由于侵入周围组织,我们无法去除整个肿瘤。切除肿瘤的病理学检查显示前列腺腺癌。对残留肿瘤进行外部光束放射治疗和高剂量速率近距离放射治疗(HDR-BT)。在疾病的临床过程中观察到轻度纵隔淋巴结肿胀。因此,在放射治疗后用Abiraatorone给予雄激素剥夺治疗,并且前列腺特异性抗原水平降低到未检测到的水平。治疗前列腺癌的经细胞体近距离放射治疗后的生化失败应被视为会阴复发。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号